{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:36:56Z","timestamp":1777361816418,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors of treatment switching across different countries, DMTs, and time periods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this retrospective, observational study was to identify independent predictors of treatment switching in a population of relapsing-remitting MS (RRMS) patients in the Big Multiple Sclerosis Data Network of national clinical registries, including the Italian MS registry, the OFSEP of France, the Danish MS registry, the Swedish national MS registry, and the international MSBase Registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cohort study, we merged information on 269,822 treatment episodes in 110,326 patients from 1997 to 2018 from five clinical registries. Patients were included in the final pooled analysis set if they had initiated at least one DMT during the relapsing-remitting MS (RRMS) stage. Patients not diagnosed with RRMS or RRMS patients not initiating DMT therapy during the RRMS phase were excluded from the analysis. The primary study outcome was treatment switching. A multilevel mixed-effects shared frailty time-to-event model was used to identify independent predictors of treatment switching. The contributing MS registry was included in the pooled analysis as a random effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Every one-point increase in the Expanded Disability Status Scale (EDSS) score at treatment start was associated with 1.08 times the rate of subsequent switching, adjusting for age, sex, and calendar year (adjusted hazard ratio [aHR] 1.08; 95% CI 1.07\u20131.08). Women were associated with 1.11 times the rate of switching relative to men (95% CI 1.08\u20131.14), whilst older age was also associated with an increased rate of treatment switching. DMTs started between 2007 and 2012 were associated with 2.48 times the rate of switching relative to DMTs that began between 1996 and 2006 (aHR 2.48; 95% CI 2.48\u20132.56). DMTs started from 2013 onwards were more likely to switch relative to the earlier treatment epoch (aHR 8.09; 95% CI 7.79\u20138.41; reference = 1996\u20132006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Switching between DMTs is associated with female sex, age, and disability at baseline and has increased in frequency considerably in recent years as more treatment options have become available. Consideration of a patient's individual risk and tolerance profile needs to be taken into account when selecting the most appropriate switch therapy from an expanding array of treatment choices.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1274194","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:20:19Z","timestamp":1703254819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of treatment switching in the Big Multiple Sclerosis Data Network"],"prefix":"10.3389","volume":"14","author":[{"given":"Tim","family":"Spelman","sequence":"first","affiliation":[]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[]},{"given":"Anneke","family":"Van Der Walt","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Trojano","sequence":"additional","affiliation":[]},{"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[]},{"given":"Dana","family":"Hor\u00e1kov\u00e1","sequence":"additional","affiliation":[]},{"given":"Jir\u00ed","family":"Drahota","sequence":"additional","affiliation":[]},{"given":"Fabio","family":"Pellegrini","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Hyde","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Duquette","sequence":"additional","affiliation":[]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[]},{"given":"Seyed Aidin","family":"Sajedi","sequence":"additional","affiliation":[]},{"given":"Patrice","family":"Lalive","sequence":"additional","affiliation":[]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[]},{"given":"Marc","family":"Girard","sequence":"additional","affiliation":[]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[]},{"given":"Francois","family":"Grand'Maison","sequence":"additional","affiliation":[]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[]},{"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[]},{"given":"Maria Jose","family":"Sa","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gerlach","sequence":"additional","affiliation":[]},{"given":"Yolanda","family":"Blanco","sequence":"additional","affiliation":[]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[]},{"given":"Ayse","family":"Altintas","sequence":"additional","affiliation":[]},{"given":"Stella","family":"Hughes","sequence":"additional","affiliation":[]},{"given":"Pamela","family":"McCombe","sequence":"additional","affiliation":[]},{"given":"Radek","family":"Ampapa","sequence":"additional","affiliation":[]},{"given":"Koen","family":"de Gans","sequence":"additional","affiliation":[]},{"given":"Chris","family":"McGuigan","sequence":"additional","affiliation":[]},{"given":"Aysun","family":"Soysal","sequence":"additional","affiliation":[]},{"given":"Julie","family":"Prevost","sequence":"additional","affiliation":[]},{"given":"Nevin","family":"John","sequence":"additional","affiliation":[]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[]},{"given":"Leszek","family":"Stawiarz","sequence":"additional","affiliation":[]},{"given":"Ali","family":"Manouchehrinia","sequence":"additional","affiliation":[]},{"given":"Lars","family":"Forsberg","sequence":"additional","affiliation":[]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Glaser","sequence":"additional","affiliation":[]},{"given":"Luigi","family":"Pontieri","sequence":"additional","affiliation":[]},{"given":"Hanna","family":"Joensen","sequence":"additional","affiliation":[]},{"given":"Peter Vestergaard","family":"Rasmussen","sequence":"additional","affiliation":[]},{"given":"Tobias","family":"Sejbaek","sequence":"additional","affiliation":[]},{"given":"Mai Bang","family":"Poulsen","sequence":"additional","affiliation":[]},{"given":"Jeppe Romme","family":"Christensen","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Kant","sequence":"additional","affiliation":[]},{"given":"Morten","family":"Stilund","sequence":"additional","affiliation":[]},{"given":"Henrik","family":"Mathiesen","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Hillert","sequence":"additional","affiliation":[]},{"name":"The Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"B1","first-page":"1","article-title":"Multiple sclerosis: II. Diagnosis and symptoms management","volume":"4","author":"Fymat","year":"2023","journal-title":"J Neurol Psychol Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: Data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00415-020-10226-6","article-title":"Comparative analysis of dimethyl fumarate and fingolimod in relapsing\u2013remitting multiple sclerosis","volume":"268","author":"Lorscheider","year":"2021","journal-title":"J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0250820","DOI":"10.1371\/journal.pone.0250820","article-title":"Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry","volume":"16","author":"Papp","year":"2021","journal-title":"PLoS ONE."},{"key":"B6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.msard.2018.11.004","article-title":"Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study","volume":"27","author":"Setayeshgar","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","article-title":"Adherence and persistence to drug therapies for multiple sclerosis: a population-based study","volume":"8","author":"Evans","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1352458515594041","article-title":"The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis","volume":"22","author":"Warrender-Sparkes","year":"2016","journal-title":"Multiple Sclerosis J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"103076","DOI":"10.1016\/j.msard.2021.103076","article-title":"How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP)","author":"Bigaut","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.msard.2020.102124","article-title":"Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)","volume":"42","author":"Patti","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis\u2014insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fneur.2021.647811","article-title":"Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network","volume":"12","author":"Hillert","year":"2021","journal-title":"Front Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-020-0906-6","article-title":"Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis","volume":"20","author":"St\u00fchler","year":"2020","journal-title":"BMC Med Res Methodol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/1352458519881558","article-title":"A roadmap to precision medicine for multiple sclerosis","volume":"26","author":"Chitnis","year":"2020","journal-title":"Multiple Scler J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.msard.2020.101928","article-title":"Predictive medicine in multiple sclerosis: a systematic review","volume":"40","author":"Havas","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13524585211010128","DOI":"10.1177\/13524585211010128","article-title":"Early treatment delays long-term disability accrual in RRMS: results from the BMSD network","volume":"27","author":"Iaffaldano","year":"2021","journal-title":"Multiple Sclerosis J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1177\/1352458519848965","article-title":"The MSBase registry: informing clinical practice","volume":"25","author":"Kalincik","year":"2019","journal-title":"Multiple Scler J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ane.12425","article-title":"The Swedish MS registry\u2013clinical support tool and scientific resource","volume":"132","author":"Hillert","year":"2015","journal-title":"Acta Neurol Scand."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish multiple sclerosis registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"key":"B21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10072-018-3610-0","article-title":"The Italian multiple sclerosis register","volume":"40","author":"Trojano","year":"2019","journal-title":"Neurol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): a unique multimodal nationwide MS registry in France","volume":"26","author":"Vukusic","year":"2020","journal-title":"Multiple Scler J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"104477","DOI":"10.1016\/j.msard.2022.104477","article-title":"Switching to natalizumab or fingolimod in multiple sclerosis: comparative effectiveness and effect of pre-switch disease activity","volume":"70","author":"Spelman","year":"2023","journal-title":"Multiple Scler Relat Disor."},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1536867X0200200102","article-title":"Parametric frailty and shared frailty survival models","volume":"2","author":"Gutierrez","year":"2002","journal-title":"Stata J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e38661","DOI":"10.1371\/journal.pone.0038661","article-title":"Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome","volume":"7","author":"Meyniel","year":"2012","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1093\/brain\/awx185","article-title":"Towards personalized therapy for multiple sclerosis: prediction of individual treatment response","volume":"140","author":"Kalincik","year":"2017","journal-title":"Brain."},{"key":"B27","doi-asserted-by":"publisher","first-page":"102686","DOI":"10.1016\/j.msard.2020.102686","article-title":"First line treatment failure: Predictive factors in a cohort of 863 relapsing remitting MS patients","volume":"48","author":"Ayrignac","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"102813","DOI":"10.1016\/j.msard.2021.102813","article-title":"Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS","volume":"50","author":"Sorensen","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"103361","DOI":"10.1016\/j.msard.2021.103361","article-title":"Factors driving delayed time to multiple sclerosis diagnosis: results from a population-based study","volume":"57","author":"Patti","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40120-018-0112-1","article-title":"European and American guidelines for multiple sclerosis treatment","volume":"7","author":"Ghezzi","year":"2018","journal-title":"Neurol Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1212\/CON.0000000000000738","article-title":"Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Continuum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1212\/CON.0000000000001170","article-title":"Treatment of multiple sclerosis","volume":"28","author":"Cross","year":"2022","journal-title":"Continuum."},{"key":"B36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1212\/NXI.0000000000000636","article-title":"An argument for broad use of high efficacy treatments in early multiple sclerosis","volume":"7","author":"Stankiewicz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflam."},{"key":"B37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","article-title":"Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm","volume":"32","author":"Cree","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/13524585221139156","article-title":"Improving the decision to switch from first-to second-line therapy in multiple sclerosis: a dynamic scoring system","volume":"29","author":"Sabath\u00e9","year":"2023","journal-title":"Multiple Scler J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1756286420975223","DOI":"10.1177\/1756286420975223","article-title":"Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease","volume":"13","author":"Berger","year":"2020","journal-title":"Ther Adv Neurol Disord."},{"key":"B40","doi-asserted-by":"publisher","first-page":"104526","DOI":"10.1016\/j.msard.2023.104526","article-title":"Pregnancy planning and management for women with multiple sclerosis: what has changed over the last 15 years? An Italian single-center experience","author":"Toscano","year":"2023","journal-title":"Multiple Scler Relat Disor."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1274194\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:20:24Z","timestamp":1703254824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1274194\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":40,"alternative-id":["10.3389\/fneur.2023.1274194"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1274194","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"article-number":"1274194"}}